These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37393304)

  • 1. Long-term evaluation of the seroprevalence of SARS-CoV-2 IgG and IgM antibodies in recovered patients: a meta-analysis.
    Li Q; Chen L; Li F; He A
    BMC Infect Dis; 2023 Jul; 23(1):444. PubMed ID: 37393304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.
    Hajissa K; Islam MA; Hassan SA; Zaidah AR; Ismail N; Mohamed Z
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the COVID-19 pandemic progression in Ecuador through seroprevalence analysis of anti-SARS-CoV-2 IgG/IgM antibodies in blood donors.
    Gaviria A; Tamayo-Trujillo R; Paz-Cruz E; Cadena-Ullauri S; Guevara-Ramírez P; Ruiz-Pozo VA; Cevallos F; Aguirre-Tello V; Risueño K; Yánez MP; Cabrera-Andrade A; Zambrano AK
    Front Cell Infect Microbiol; 2024; 14():1373450. PubMed ID: 38975325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis.
    Wang P; Ni J; Chu YY; Chen QQ; Wu GC; Fang Y; Chen C; Zhang RD; Jiang LQ; Zhao Y; Fang X; He J; Wang DG; Wang GH; Pan HF
    Biomed Pharmacother; 2022 Jun; 150():112997. PubMed ID: 35486976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of Immunoglobulin M and G Antibodies against SARS-CoV-2 Virus: A Systematic Review and Meta-Analysis Study.
    Fathi M; Vakili K; Sayehmiri F; Mohamadkhani A; Ghanbari R; Hajiesmaeili M; Rezaei-Tavirani M
    Iran J Immunol; 2021 Mar; 18(1):34-46. PubMed ID: 33787512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya.
    Awandu SS; Ochieng Ochieng A; Onyango B; Magwanga RO; Were P; Atieno Ochung' A; Okumu F; Oloo MA; Katieno JS; Lidechi S; Ogutu F; Awuor D; Kirungu JN; Orata F; Achieng J; Oure B; Nyunja R; Muok EMO; Munga S; Estambale B
    PLoS One; 2022; 17(12):e0272751. PubMed ID: 36548358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rate of SARS-CoV-2 among asymptomatic non-immunised low-risk parturient women between the two waves.
    Al-Hussaini TK; EzzEldin AM; Shaaban OM; Abdel-Aleem MA; Kamal DT; Ibrahim MN
    J Obstet Gynaecol; 2022 Aug; 42(6):1868-1873. PubMed ID: 35484953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo.
    Batchi-Bouyou AL; Lobaloba Ingoba L; Ndounga M; Vouvoungui JC; Mfoutou Mapanguy CC; Boumpoutou KR; Ntoumi F
    Int J Infect Dis; 2021 May; 106():3-7. PubMed ID: 33370565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data.
    Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Oliveros-Acebes E; García-Navarro MJ; Khosravi-Shahi P
    Cancer Treat Rev; 2020 Nov; 90():102102. PubMed ID: 32947121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of SARS-CoV-2 IgG antibodies among health care workers prior to vaccine administration in Europe, the USA and East Asia: A systematic review and meta-analysis.
    Hossain A; Nasrullah SM; Tasnim Z; Hasan MK; Hasan MM
    EClinicalMedicine; 2021 Mar; 33():100770. PubMed ID: 33718853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence and characteristics of Coronavirus Disease (COVID-19) in workers with non-specific disease symptoms.
    Javed W; Abidi SHB; Baqar JB
    BMC Infect Dis; 2022 May; 22(1):481. PubMed ID: 35596145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of IgM and IgG Against SARS-CoV-2 after Two Doses of Pfizer-BioNTech COVID-19 Vaccine in Women with Breast Cancer.
    Almehmadi M; Salih MM; Shafie A; Alsharif A; Alsiwiehr N; El-Askary A; Alzahrani K; Al-Hazmi A; Aljuaid A; Abdulazziz O; Almalki AA; Allahyani M; Eed E; Alharbi AM; Halawi M; Allam HH; Abutawil H; Alosimi E; Gharib AF
    Clin Lab; 2022 Nov; 68(11):. PubMed ID: 36378000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Lateral Flow Immunoassay COVIDTECH
    Exinger J; Hartard C; Lafferrière F; Fenninger C; Charbonnière LJ; Jeulin H
    Jpn J Infect Dis; 2022 Jul; 75(4):334-340. PubMed ID: 34980703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.
    Tang Y; Sun J; Yuan Y; Yao F; Zheng B; Yang G; Xie W; Ye G; Li Z; Jiao X; Li Y
    BMC Infect Dis; 2022 Jan; 22(1):10. PubMed ID: 34983429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of IgM and IgG in Serum of COVID-19 Diabetic Patients After Recovery.
    Almehmadi M
    Clin Lab; 2022 Mar; 68(3):. PubMed ID: 35254016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of SARS-CoV-2 Infection Evaluated by Immunochromatographic Rapid Testing for the Determination of IgM and IgG Against SARS-CoV-2 in a Cohort of Mask Wearing Workers in the Metal-Mechanical Sector in an Area With a High Incidence of COVID-19.
    Esposito S; Neglia C; Affanni P; Colucci ME; Argentiero A; Veronesi L; Messina G; Deolmi M; Principi N;
    Front Public Health; 2021; 9():628098. PubMed ID: 34249830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.